MDRP’s All New Pharmaceutical VA Contracting and Compliance Full-Day Summit

Your successful compliance with the VA’s contractual and statutory requirements can spell the difference between profitable partnerships and drawn-out audits — and those contracts are up for re-negotiation in 2014. Are you ready?

Are you prepared to install and maintain the data tracking and submission systems that your contractual obligations require?

This year at the 18th Annual Medicaid Drug Rebate Program we are happy to announce the addition of the brand-new Pre-Conference event titled, “Pharmaceutical VA Contracting and Compliance Summit.” This full-day summit is ideal for pharmaceutical and biotech manufacturers looking to comprehensively tackle the challenges of designing and complying with the complex — but highly lucrative — contracts in this sector.

Over the course of the day on September 9, you will touch upon key steps necessary to ensure you are ready for 2014. Below are just a few session highlights: 

- Guarantee Open and Effective Communication with your Contract Officer Gregory Madden, Senior Contract Specialist, Federal Supply Schedule Service, Department of Veteran’s Affairs 

- Quantify and Avoid Penalties from Trade Agreement Act Non-Compliance Melbourne Noel, former Senior Contracts Attorney, Office of General Counsel, Department of Veteran’s Affairs (ret.)

- Prepare for Contract Re-Negotiation in 2014 and Beyond Tom Evegan, Associate Director, Contracts and Pricing, Finance, Acorda Therapeutics

Want to learn more? Download our brochure.

As a reader of the healthcare insights blog, you receive an exclusive discount of 15% off of the standard price by using priority code XP1858BLOG to register. Do you have any questions about the event? Feel free to contact Kate Devery at kdevery@iirusa.com or visit the webpage.

Cheers,
The Medicaid Drug Rebate Program Summit Team

Medicaid Drug Rebate Program Summit Webpage
Follow Us on Twitter

A Call For Papers: HIX Reloaded

We are pleased to announce HIX Reloaded (formerly the Health Insurance Exchange Congress), taking place the week of November 11 in Baltimore. We’re playing in a dynamic marketplace, where seemingly every day there’s new information, guidance and regulations when it comes to healthcare reform, and more specifically, health insurance marketplaces. In a marketplace laced with uncertainty, constant change, and unclear guidelines, HIX Reloaded brings together early HIX adopters and entrants to share their lessons, discuss anticipated challenges ahead. When attendees register, they will be asked to vote on the topics that matter most to them, thus ensuring a timely, relevant agenda.

The agenda is currently under development, and I am currently looking for health plan and state government speakers who have first-hand experience on in the following areas:

-budget neutral risk adjustment

-network development & expansion

-state/health plan collaboration

-case studies on marketing your plan to grow membership

-training Navigators

-strategies to maintain continuity of care

-setting and negotiating provider rates

For information about last year’s agenda visit our website.

If you are interested in speaking on any of these topics, or would like to suggest another topic, please email SGordon@iirusa.com, the Program Director for the event.

If you would like to get in front of our audience of health plan executives working on exchanges, please contact Sarah Scarry at SScarry@iirusa.com for sponsorship and exhibition opportunities.

We look forward to hearing from you soon!

Cheers,
The HIX Reloaded Team

Who can you meet at the Gross-to-Net Accounting Forum?

The Gross-to-Net Accounting Forum is less than a month away, taking place June 17-18 in Boston. Demand from small to mid-size pharma companies has been extremely high, indicating how timely and relevant GTN content is to your business—and bottom line.

As in most industries, small to mid-sized biopharmaceutical manufacturers have different challenges from their larger counterparts. In the Gross-to-Net space, while larger companies have a variety of people across several functions involved in the process, smaller companies make do with far fewer resources. Join the following small-mid size companies that are coming to GTN to find the solutions to their problems and yours alike:

•	Actient	•	Leo Pharma
•	AMAG	•	Neos Therapeutics
•	ARIAD	•	Purdue
•	Covidien	•	Salix
•	Exelixis	•	Shionogi Inc.
•	Forest Laboratories	•	Sunovion
•	Grifols	•	Vertex
•	Jazz Pharmaceuticals	•	Vertical / Trigen

Attend these spotlight sessions to help your bottom line: 

• Process Evaluation for Small to Mid-Sized Pharmaceutical Companies
• Benchmark Your Gross-to-Net Processes, Systems & Methodologies: Top 10 GTN Hot Topics
• Account for the Government Pricing and Contracting Impact on Gross-to-Net Calculations
• Commercial Contracts and Gross-to-Net for Managed Care

To view our full program, download our brochure.

As a reader of the Healthcare Insights Blog you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you next month!

Best,
The Pharmaceutical Accounting, Financial, & Reporting Team

Visit our Homepage
Follow us on Twitter

Look Who’s Attending the Gross-to-Net Forum

The Gross-to-net Accounting Forum will be here before you know it—seats are filling up rapidly!

Since its introduction, the buzz for this event has been building more and more each week, with positive feedback from our growing attendee list. Join us and the confirmed attendees from the following companies to ensure you do not miss out on learning the newest developments in the GTN process.

Acorda Therapeutics*Actient Pharmaceuticals*Afaxys, Inc*Alliance Life Sciences Consulting*AMAG Pharmaceuticals Inc*Amgen*Amneal Pharmaceuticals*APP Pharmaceuticals, LLC*ARIAD Pharmaceuticals Incorporated*Astellas Pharma US*AstraZeneca*Bayer HealthCare Pharmaceuticals*Boehringer Ingelheim Pharmaceuticals*BPI Technologies*Covidien*Daiichi Sankyo*DDN*Eli Lilly & Co*Exelixis*Faulkner Mackie & Cochran PC*Forest Laboratories Inc*Forest Pharmaceuticals Inc *GlaxoSmithKline*Grifols*IMS HEALTH*Incyte*Jazz Pharmaceuticals*King & Spalding LLP*LEO Pharma Inc*Millennium: The Takeda Oncology Company*Mylan*Neos Therapeutics*Optimer Pharma*PPS - Professional Provider Services Inc.*Purdue Pharma*Revitas*Salix Pharmaceuticals*Sanofi-Aventis*Shionogi Inc.*Sunovion Pharmaceuticals*Vertex Pharmaceuticals*Vertical / Trigen*Warner Chilcott

Any many more! To view our full program, download our brochure.

As a reader of the healthcare insights blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you this June!

Best,
The GTN Team

Visit our homepage
Follow us on Twitter

Session Spotlight: Case Study: Implement the Texas Price Reporting Program

Texas finalized regulations related to the Medicaid Vendor Drug Program in October of last year, for implementation to begin this March. Ever since, manufacturers have been struggling with the changes that they have caused to the second largest state’s program. So what are some of those challenges?

Session: Case Study: Implement the Texas Price Reporting Program

Speaker: Michael Hepburn, Senior Director, Government Contract Compliance, Janssen Pharmaceuticals, Inc.

Hear one manufacturer’s experience and challenges with implementing the price reporting requirements and much more. In this session, a Michael Hepburn will discuss some of the challenges that have arisen such as what constitutes a price change, direct prices vs. indirect prices and reconciling data to financial records and source systems.

Want to learn more? Download our brochure.

The 18th Annual Medicaid Drug Rebate Program takes place September 9-11 in Chicago, IL. To learn more visit our webpage. As a reader of the healthcare insights blog, you receive an exclusive discount of 15% off of the standard price by using priority code XP1858BLOG to register. We look forward to seeing you this fall!

Session Spotlight: Process Evaluation for Small to Mid-Sized Pharmaceutical Companies

Gross-to-Net calculations are not just for big pharma. While the larger organizations have a variety of people across several functions involved in the process, smaller companies make do with far fewer resources. In this session, leaders in smaller pharmaceutical companies address unique challenges inherent to companies their size and much more. 

Session: Process Evaluation for Small to Mid-Sized Pharmaceutical Companies

Speakers:
Paul Troiano, Senior Director, Commercial Finance, OPTIMER PHARMACEUTICALS
 Alberto Bonilla, Director, Commercial Finance, WARNER CHILCOTT

It’s not a new story that smaller pharmaceutical companies often have a more difficult time than their larger counterparts. One person might have the same function as four different people at a larger company. This session discusses some of the additional challenges such as who should be involved in estimating GTN and to what capacity, and how professionals devise estimates when the company lacks a large number of products to draw analogies from and how do they estimate returns.

Want to learn more? Download our brochure.

The Gross-to-Net Accounting Forum takes place June 17-18 in Boston, MA. As a reader of this blog you'll receive 15% off the standard rate by using code XP1811BLOG when you register. We look forward to seeing you this June!

Session Spotlight: Screenings, Biomarkers & Diagnostic Testing to Manage Outcomes and Costs

Advances in our understanding of the genetic mutations and alterations and resultant expression are leading to the identification of more and more biomarkers to help direct patient management. Biomarker development and applications are being seen in early detection, prognosis, toxicity profiling, predictive, effective monitoring, follow up, etc.

IIR’s Collaborative Summit for Oncology brings together a multi-stakeholder view of the current state of biomarker use and how the use of these applications will lead to less toxic care. They will also discuss insights into what you can expect to see in the next 3-5 years to increase positive outcomes and manage costs of oncology.

SESSION SPOTLIGHT:  The Use of Screenings, Biomarkers & Diagnostic Testing to Increase Positive Outcomes and Manage Cost of Oncology

Moderator: Paul Howard, Director and Senior Fellow Center for Medical Progress, Manhattan Institute for Policy Research

Panelists:

• William T. McGivney, PhD, Former NCCN CEO, McGivney Global Advisors
• Oscar Puig, Biomarker Lead in Oncology, Translational Clinical Research Center, Roche
• Maurie Markman, MD, Senior Vice President, Clinical Affairs, Cancer Treatment Centers of America

To learn more, download our brochure.

As a reader of the healthcare insights blog, you can use priority code XP1814BLOG to receive 15% off of the standard rate to register. If you have any questions or need any further information, feel free to email kdevery@iirusa.com or visit the webpage.

We look forward to seeing you in June!

Best,
Oncology Management Team

Visit the Oncology Management Webpage
Follow us on Twitter

Session Spotlight: Account for the Government Pricing and Contracting Impact on Gross-to-Net Calculations

As the largest healthcare provider to the American population, the US government has a significant impact on pharmaceutical company financials. With Medicaid expansion continuing into 2014, this impact is only going to grow. Manufacturers must calculate prices for each product, along with the reimbursement rate on each prescription. These rebates make GTN calculations a time-consuming endeavor for finance divisions, so what is the best way to proceed?

Session: Account for the Government Pricing and Contracting Impact on Gross-to-Net Calculations

Speaker: Jennifer Norton, Senior Director, Pricing & Contract Administration - Managed Markets, Vertex Pharmaceuticals , Inc.

The US Government is the largest healthcare provider to the American population and therefore has a significant impact on pharmaceutical company financials. Each day we hear of another state’s decision whether or not to expand Medicaid, as is their option. As some states decide to expand, the government’s impact on company financials will only continue to grow. Government reimbursement and rebates have a direct impact on GTN calculations. In this session, executives from Vertex Pharmaceuticals will discuss how government pricing and contracting affects GTN and the operational challenges that arise that affect that calculation.

Want to learn more? Download our brochure.

The Gross-to-Net Accounting Forum takes place June 17-18 in Boston, MA. As a reader of this blog you'll receive 15% off the standard rate by using code XP1811BLOG when you register. We look forward to seeing you this June!